AnaptysBio plans to separate biopharma ops from royalty assets by YE 2026; Q3 net income $15.1M

ANAPTYSBIO, INC

Intent to split into two public companies, one holding Jemperli royalties and milestones, the other advancing pipeline assets.
Q3 2025 revenue $76.3M (up from $30.0M), net income $15.1M ($0.54/share) vs net loss of $32.9M in Q3 2024.
Cash and investments $256.7M; expects ~$300M YE 2025 including $75M milestone from GSK when Jemperli hits $1B sales.
Phase 2 top-line data for rosnilimab in ulcerative colitis expected Nov/Dec 2025; Phase 2b RA data positive.
GSK's Jemperli Q3 sales $303M (+16% QoQ); annualized royalties for Anaptys >$390M at peak guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.